The FDA has recently approved new tools to combat respiratory syncytial virus (RSV), including a monoclonal antibody injection called Beyfortus for newborns and infants, as well as RSV vaccines for adults aged 60 and older. These breakthroughs represent significant progress in RSV prevention, particularly for vulnerable populations, and offer hope for future vaccines for children. For more in-depth information, please refer to the full article from Baptist Health titled, Relief from RSV.